Skip to main content

Virtual visit appointments available 7 days a week from 9:00am to 11:00pm. Learn More

COVID-19 Updates

COVID-19 Updates: Get the latest on vaccine information, in-person appointments, virtual visits and more. Learn More

Notice: Street Closure

Street Closure: Texas Medical Center Campus road closures, September 29 - October 1, that will impact patients and visitors. Learn More | En Español


Texas Medical Center

Phone: 832-822-4292
Fax: 832-825-4294


6701 Fannin Street
Wallace Tower, Suite 1560
Houston, TX 77030

Carlos A. Bacino, MD, FACMG

Chief, Genetics Service

Vice Chair Clinical Affairs, Dept. of Molecular and Human Genetics, Baylor College of Medicine
Professor, Baylor College of Medicine


School Education Degree Year
Cedars-Sinai Medical Center Fellowship Genetics 1994
Beth Israel Medical Center Program Residency Pediatrics 1991
Beth Israel Medical Center Program Internship Pediatrics 1989
Nat'l Inst of Medical Genetics-Buenos Aires Residency Medical Genetics 1983
Universidad de Buenos Aires Medical School Doctor of Medicine 1981


I am dedicated to clinical as well as research activities in the Department of Molecular and Human Genetics. In the clinical area, I am involved in the diagnosis and management of patients with birth defects and a variety of genetic disorders and participate in the Skeletal Dysplasia Clinic. In the research arena, I am the Director of the Angelman Syndrome Clinic and the Medical Director of the Baylor Genetics Cytogenetics Laboratory, and have a particular interest in structural chromosome abnormalities and genomic disorders. In addition, I have a special interest in two conditions in which I am involved in clinical research:

Achondroplasia:  Our group has been involved in multiple clinical trials in achondroplasia. the most common form of dwarfism. We have ongoing trials sponsored by pharmaceutical companies BioMarin, Ascendis, Pfizer and Sanofi.

Angelman Syndrome and Disorders of Imprinting: We have participated in multiple clinical trials in Angelman syndrome for the last 20 years. In collaboration with Hoffman-La Roche and IONIS Pharmaceutical, we have been involved in two cutting-edge clinical trial studies using antisense oligonucleotides (a genetic modifying therapy) that aim to improve the lives and medical problems associated with Angelman syndrome.

I am the PI in conjunction with Dr. Brendan for one of the sites of the Undiagnosed Diseases Network (UDN). This network brings families across the US with ultrarare diseases and is supported by the National Institutes of Health (NIH) and seeks to provide answers to patient and families affected with these mysterious conditions.


Organization Name Role
American Board of Medical Genetics and Genomics Member, Board of Directors
American College of Medical Genetics Member
American Society of Human Genetics Member
National Institutes of Health and Child Development (NICHD) Advisory Council Member
Society for Pediatric Research Member
Teratology Society Member

Selected Publications

Savarirayan R, Irving M, Harmatz P, Delgado B, Wilcox WR, Philips J, Owen N, Bacino CA, Tofts L, Charrow J, Polgreen LE, Hoover-Fong J, Arundel P, Ginebreda I, Saal HM, Basel D, Font RU, Ozono K, Bober MB, Cormier-Daire V, Le Quan Sang KH, Baujat G, Alanay Y, Rutsch F, Hoernschemeyer D, Mohnike K, Mochizuki H, Tajima A, Kotani Y, Weaver DD, White KK, Army C, Larrimore K, Gregg K, Jeha G, Milligan C, Fisheleva E, Huntsman-Labed A, Day J. Growth parameters in children with achondroplasia: A 7-year, prospective, multinational, observational study. Genet Med. 2022 Dec;24(12):2444-2452. PMID: 36107167

Savarirayan R, Tofts L, Irving M, Wilcox WR, Bacino CA, Hoover-Fong J, Font RU, Harmatz P, Rutsch F, Bober MB, Polgreen LE, Ginebreda I, Mohnike K, Charrow J, Hoernschemeyer D, Ozono K, Alanay Y, Arundel P, Kotani Y, Yasui N, White KK, Saal HM, Leiva-Gea A, Luna-González F, Mochizuki H, Basel D, Porco DM, Jayaram K, Fisheleva E, Huntsman-Labed A, Day JRS. Safe and persistent growth-promoting effects of vosoritide in children with achondroplasia: 2-year results from an open-label, phase 3 extension study. Genet Med. 2021 Aug 2:1-5. PMID: 34341520

Duis J, Nespeca M, Summers J, Bird L, Bindels-de Heus KGCB, Valstar MJ, de Wit MY, Navis C, Ten Hooven-Radstaake M, van Iperen-Kolk BM, Ernst S, Dendrinos M, Katz T, Diaz-Medina G, Katyayan A, Nangia S, Thibert R, Glaze D, Keary C, Pelc K, Simon N, Sadhwani A, Heussler H, Wheeler A, Woeber C, DeRamus M, Thomas A, Kertcher E, DeValk L, Kalemeris K, Arps K, Baym C, Harris N, Gorham JP, Bohnsack BL, Chambers RC, Harris S, Chambers HG, Okoniewski K, Jalazo ER, Berent A, Bacino CA, Williams C, Anderson A. A multidisciplinary approach and consensus statement to establish standards of care for Angelman syndrome. Mol Genet Genomic Med. 2022 Feb 11. PMID: 35150089.

View PubMed Publications 


English, Spanish

* Texas Children's Hospital physicians' licenses and credentials are reviewed prior to practicing at any of our facilities. Sections titled From the Doctor, Professional Organizations and Publications were provided by the physician's office and were not verified by Texas Children's Hospital.